Altogether, our data suggest that pemetrexed or 5-FU-induced PD-L1 upregulation in NSCLC cells can modulate T-cell activation when combined with PD-1/PD-L1 blockade, while addition of cisplatin or PTX did not have such immunomodulatory effects. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.